SEARCH

SEARCH BY CITATION

References

  • Aledort, L.M., Hayward, C.P., Chen, M.G., Nichol, J.L. & Bussel, J. (2004) Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. American Journal of Hematology, 76, 205213.
  • Ballem, P.J., Segal, G.M., Stratton, J.R., Gernsheimer, T., Adamson, J.W. & Slichter S.J. (1987) Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenia purpura. Evidence of both impaired platelet production and increased platelet clearance. Journal of Clinical Investigation, 80, 3340.
  • Basser, R.L., O'Flaherty, E., Green, M., Edmonds, M., Nichol, J., Menchaca, D.M., Cohen, B. & Begley, C.G. (2002) Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood, 99, 25992602.
  • Berchtold, P. & McMillan, R. (1989) Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood, 74, 23092317.
  • Bottiger, L.E. & Westerholm, B. (1972) Thrombocytopenia. I. Incidence and aetiology. Acta Medica Scandinavica, 191, 535540.
  • Broudy, V.C. & Lin, N.L. (2004) AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine, 25, 5260.
  • Debili, N., Wendling, F., Katz, A., Guichard, J., Breton-Gorius, J., Hunt, P. & Vainchenker, W. (1995) The Mpl-ligand of thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood, 86, 25162525.
  • George, J.N., El Harake, M.A. & Aster, R.H. (1995) Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms. In: Williams Hematology (ed. by E.Beutler, M.A.Lichtman, B.S.Coller, J.J.Kipps & U.Seligsohn), 6th edn, pp. 13151355. McGraw-Hill, New York.
  • George, J.N., Woolf, S.H., Raskob, G.E., Wasser, J.S., Aledort, L.M., Ballem, P.J., Blanchette, V.S., Bussel, J.B., Cines, D.B., Kelton, J.G., Lichtin, A.E., McMillan, R., Okerbloom, J.A., Regan, D.H. & Warrier, I. (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood, 88, 340.
  • Heyns, A.D., Lotter, M.G., Badenhorst, P.N., De Kock, F., Pieters, H., Herbst, C., Van Reenen, O.R., Kotze, H. & Minnaar, P.C. (1982) Kinetics and sites of destruction of 111 Indium-oxine-labeled platelets in idiopathic thrombocytopenic purpura: a quantitative study. American Journal of Hematology, 12, 167177.
  • Heyns A. D., Badenhorst, P.N., Lotter, M.G., Pieters, H., Wessels, P. & Kotze, H.F. (1986) Platelet turnover and kinetics in immune thrombocytopenic purpura: results with autologous 111 ln-labeled platelets and homologous 51 Cr-labeled platelets differ. Blood, 67, 8692.
  • Kelton, J.G. & Gibbons, S. (1982) Autoimmune platelet destruction: idiopathic thrombocytopenic purpura. Seminars in Thrombosis and Hemostasis, 8, 83104.
  • Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M. & Kuter, D.J. (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood, 98, 32413248.
  • McMillan, R. (1981) Chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine, 304, 11351147.
  • McMillan, R. (1997) Therapy for adults with refractory chronic immune thrombocytopenic purpura. Annals of Internal Medicine, 126, 307314.
  • Methia, N., Louache, F., Vainchenker, W. & Wendling, F. (1993) Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood, 82, 13951401.
  • Nichol, J.L. (1998) The Mpl ligand and platelet homeostasis. Acta Paediatrica. Supplement, 424, 715.
  • Provan, D. & Newland, A.C. (2002) Fifty years of idiopathic thrombocytopenic purpura: management of refractory ITP in adults. British Journal of Haematology, 118, 933944.
  • Provan, D., Newland, A.C., Norfolk, D., Bolton-Maggs, P., Lilleyman, J., Greer, I., May, A., Murphy, M., Ouwehand W. & Watson S. (2003) Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. British Journal of Haematology, 120, 574596.
  • Sheridan, W.P., Choi, E., Toombs, C.F., Nichol, J., Fanucchi, M.W., Basser, R.I. (1997) Biology of thrombopoiesis and the role of the Mpl ligand in the production and function of platelets. Platelets, 8, 319332.
  • Siegel, R.S., Rae, J.L., Barth, S., Coleman, R.E., Reba, R.C., Kurlander, R. & Rosse, W.F. (1989) Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. American Journal of Hematology, 30, 206212.
  • Stoll, D., Cines, D.B., Aster, R.H. & Murphy, S. (1985) Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood, 65, 584588.
  • Wang, B., Nichol, J.L. & Sullivan, J.T. (2004) Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clinical Pharmacology and Therapeutics, 76, 628638.